Comment on: FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
Not available.
Saved in:
| Main Authors: | Qian Yan, Jinlin Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-01-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11925 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies
by: Pierre Peterlin, et al.
Published: (2024-11-01) -
The Clinical Safety and Efficacy of Cytarabine and Daunorubicin Liposome (CPX‐351) in Acute Myeloid Leukemia Patients: A Systematic Review
by: Abdulwahab M. Alzahrani, et al.
Published: (2025-05-01) -
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients
by: Christina Rautenberg, et al.
Published: (2025-04-01) -
Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis.
by: Li-Hong Shou, et al.
Published: (2017-01-01) -
CASE PRESENTATION: TREATMENT AND FOLLOW-UP EXPERIENCE FROM MYELODYSPLASTIC SYNDROME (MDS) REAB II TO CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
by: Harika Shundo, et al.
Published: (2024-12-01)